{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:08:12Z","timestamp":1757311692644,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"UHK","award":["Excellence project"],"award-info":[{"award-number":["Excellence project"]}]},{"name":"UHHK","award":["Long-term development plan"],"award-info":[{"award-number":["Long-term development plan"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10072-018-3551-7","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T05:10:52Z","timestamp":1535951452000},"page":"2115-2121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The direct costs of multiple sclerosis\u2014study in the Czech Republic"],"prefix":"10.1007","volume":"39","author":[{"given":"Petra","family":"Maresova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Valis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Novotny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zby\u0161ek","family":"Pavelek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9664-1109","authenticated-orcid":false,"given":"Kamil","family":"Kuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"key":"3551_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/ana.21757","volume":"66","author":"M Trojano","year":"2006","unstructured":"Trojano M, Pellegrini F, Paolicelli D et al (2006) Real-life impact of early interferon \u03b2 therapy in relapsing multiple sclerosis. Ann Neurol 66:513\u2013520","journal-title":"Ann Neurol"},{"issue":"2_suppl","key":"3551_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1352458517708117","volume":"23","author":"E Havrdova","year":"2017","unstructured":"Havrdova E, Kobelt G, Berg J, Capsa D, Gannedahl M, Dole\u017eal T, The European Multiple Sclerosis Platform (2017) New insights into the burden and costs of multiple sclerosis in Europe: results of the Czech Republic. Mult Scler 23(2_suppl):41\u201352. \n                    https:\/\/doi.org\/10.1177\/1352458517708117","journal-title":"Mult Scler"},{"issue":"5","key":"3551_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1177\/1352458511424422","volume":"18","author":"J Blahova Dusankova","year":"2012","unstructured":"Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E (2012) Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler 18(5):662\u2013668. \n                    https:\/\/doi.org\/10.1177\/1352458511424422","journal-title":"Mult Scler"},{"issue":"2","key":"3551_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10072-014-1925-z","volume":"36","author":"M Ponzio","year":"2015","unstructured":"Ponzio M, Gerzeli S, Brichetto G, Bezzini D, Mancardi GL, Zaratin P, Battaglia MA (2015) Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. Neurol Sci 36(2):227\u2013234","journal-title":"Neurol Sci"},{"issue":"12","key":"3551_CR5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10072-016-2679-6","volume":"37","author":"P Mare\u0161ov\u00e1","year":"2016","unstructured":"Mare\u0161ov\u00e1 P, Zah\u00e1lkov\u00e1 V (2016) The economic burden of the care and treatment for people with Alzheimer\u2019s disease\u2014the outlook for the Czech Republic. Neurol Sci 37(12):1917\u20131922. \n                    https:\/\/doi.org\/10.1007\/s10072-016-2679-6","journal-title":"Neurol Sci"},{"issue":"8","key":"3551_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-016-0842-x","volume":"18","author":"I Holmerova","year":"2017","unstructured":"Holmerova I, Hort J, Rusina R et al (2017) Costs of dementia in the Czech Republic. Eur J Health Econ 18(8):979\u2013986","journal-title":"Eur J Health Econ"},{"issue":"3","key":"3551_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3233\/JAD-160484","volume":"53","author":"P Maresova","year":"2016","unstructured":"Maresova P, Klimova B, Novotny M, Kuca K (2016) Alzheimer\u2019s and Parkinson\u2019s diseases: expected economic impact on Europe\u2014a call for a uniform European strategy. JAD 53(3):1123\u20131133. \n                    https:\/\/doi.org\/10.3233\/JAD-160484","journal-title":"JAD"},{"key":"3551_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907\u2013911","journal-title":"Neurology"},{"issue":"92","key":"3551_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1474-4422(03)00663-X","volume":"3","author":"DA Dyment","year":"2004","unstructured":"Dyment DA, Ebers GC, Sadovnick AD (2004) Genetics of multiple sclerosis. Lancet Neurol 3(92):104\u2013110","journal-title":"Lancet Neurol"},{"issue":"4","key":"3551_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ana.21117","volume":"61","author":"A Ascherio","year":"2007","unstructured":"Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61(4):288\u2013299","journal-title":"Ann Neurol"},{"issue":"2","key":"3551_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.wnl.0000316802.35974.34","volume":"71","author":"A Alonso","year":"2008","unstructured":"Alonso A, Hern\u00e1n MA (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71(2):129\u2013135","journal-title":"Neurology"},{"issue":"3","key":"3551_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0303-8467(02)00036-7","volume":"104","author":"M Pugliatti","year":"2002","unstructured":"Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182\u2013191","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"3551_CR13","doi-asserted-by":"publisher","first-page":"A387","DOI":"10.1016\/j.autrev.2009.11.010","volume":"9","author":"R Milo","year":"2010","unstructured":"Milo R, Kahana E (2010) Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 9(5):A387\u2013A394","journal-title":"Autoimmun Rev"},{"unstructured":"Bart\u00e1k M, Gav\u00farov\u00e1 B (2014) Economics and social aspects of long-term care in the context of the Czech Republic and the Slovak Republic EU membership. In: Proceedings of 12th International scientific conference: economic policy in the European Union member countries, PTS I and II, vol 2015. Ostravice, Czech Republic, pp 35\u201344","key":"3551_CR14"},{"unstructured":"Dlouh\u00fd M, Bart\u00e1k M (2013) Mental health financing in six Eastern European countries 16(4):4\u201313","key":"3551_CR15"},{"issue":"9","key":"3551_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2174\/156720501209151019111448","volume":"12","author":"P Mare\u0161ov\u00e1","year":"2015","unstructured":"Mare\u0161ov\u00e1 P, Mohelsk\u00e1 H, Dolej\u0161 J, Ku\u010da K (2015) Socio-economic aspects of Alzheimer\u2019s disease. Curr Alzheimer Res 12(9):903\u2013911","journal-title":"Curr Alzheimer Res"},{"key":"3551_CR17","first-page":"2349","volume":"11","author":"H Mohelsk\u00e1","year":"2015","unstructured":"Mohelsk\u00e1 H, Mare\u0161ov\u00e1 P, Vali\u0161 M, Ku\u010da K (2015) Alzheimer disease and its treatment costs case study in the Czech. Neuropsychiatr Dis Treat 11:2349\u20132354","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"21","key":"3551_CR18","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1080\/00036846.2015.1111986","volume":"48","author":"P Mare\u0161ov\u00e1","year":"2016","unstructured":"Mare\u0161ov\u00e1 P, Mohelsk\u00e1 H, Ku\u010da K (2016) Social and family load of Alzheimer\u2019s disease. Appl Econ 48(21):1936\u20131948","journal-title":"Appl Econ"},{"unstructured":"World Health Organization (2003) Guide to producing national accounts with special applications for low-income and middle-income countries. [online] Available from: \n                    http:\/\/www.who.int\/health-accounts\/documentation\/publication_nha_guide\/en\/","key":"3551_CR19"},{"unstructured":"Drummond MF, O\u2019Brien BJ (1997) Methods for the economic evaluation of health care programs (Oxford Medical Publications), 2nd edn. Oxford Medical Publication","key":"3551_CR20"},{"key":"3551_CR21","volume-title":"Essentials of pharmacoeconomics","author":"KL Rascati","year":"2014","unstructured":"Rascati KL (2014) Essentials of pharmacoeconomics, 2nd edn. Wolters Kluwer Health\/Lippincott Williams, Philadelphia","edition":"2"},{"unstructured":"IMPULS Endowment Fund (2016) Regular output from the ReMuS registry. Available at: \n                    http:\/\/www.multiplesclerosis.cz\/docs\/160914_remus_zaverecna-zprava_2016_06_souhrnna_14_9.pdf","key":"3551_CR22"},{"unstructured":"Department of Neurology, University Hospital Hradec Kr\u00e1lov\u00e9 (2014) Available from: \n                    http:\/\/www.fnhk.cz\/neuro","key":"3551_CR23"},{"unstructured":"General Health Insurance Company (V\u0161eobecn\u00e1 zdravotn\u00ed poji\u0161\u0165ovna) (2015). Annual report 2013. [online] Available from: \n                    http:\/\/www.vzp.cz\/uploads\/document\/vzp-rocenka-2013.pdf","key":"3551_CR24"},{"issue":"21","key":"3551_CR25","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","volume":"84","author":"DM Hartung","year":"2015","unstructured":"Hartung DM, Bourdette DN, Ahmed SH et al (2015) The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology 84(21):2185\u20132192. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000001608","journal-title":"Neurology"},{"issue":"9","key":"3551_CR26","first-page":"1131","volume":"5","author":"A Torabipour","year":"2014","unstructured":"Torabipour A, Majdinasab N, Ghasemzadeh R et al (2014) A study on the direct and indirect costs of multiple sclerosis based on expanded disability status scale score in Khuzestan, Iran. Int J Prev Med 5(9):1131\u20131138","journal-title":"Int J Prev Med"},{"issue":"2","key":"3551_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.euroneuro.2010.08.002","volume":"21","author":"S Campenhausen Von","year":"2011","unstructured":"Von Campenhausen S, Winter Y, Rodrigues E, Silva A et al (2011) Costs of illness and care in Parkinson\u2019s disease: an evaluation in six countries. Eur Neuropsychopharmacol 21(2):180\u2013191","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"3551_CR28","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J 23(8):1123\u20131136","journal-title":"Mult Scler J"},{"issue":"3","key":"3551_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1586\/14737167.2014.906305","volume":"14","author":"D Szmur\u0142o","year":"2014","unstructured":"Szmur\u0142o D, Fundament T, Ziobro M, Kruntor\u00e1dov\u00e1 K, Dole\u017eal T, G\u0142ogowski C (2014) Costs of multiple sclerosis\u2014extrapolation of Czech data to Polish patients. Expert Rev Pharmacoecon Outcomes Res 14(3):451\u2013458","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"3551_CR30","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3111\/13696998.2013.778268","volume":"16","author":"G Adelman","year":"2013","unstructured":"Adelman G, Rane SG, Villa KF (2013) The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ 16(5):639\u2013647","journal-title":"J Med Econ"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-018-3551-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T19:21:51Z","timestamp":1567452111000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-018-3551-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3551"],"URL":"https:\/\/doi.org\/10.1007\/s10072-018-3551-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2018,9,3]]},"assertion":[{"value":"8 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}